Osteopore has signed a key distribution deal in Australia and New Zealand as it moves to gain a solid foothold in the oral and maxillofacial facial surgery sector.

Bone healing specialist Osteopore (ASX:OSX) has signed an exclusive three-year distribution  deal with Aussie-based MAXONIQ to deliver Osteopore’s uniquely healing products throughout Australia and New Zealand.

MAXONIQ specialises in providing solutions for complex oral and maxillofacial applications.

They have an established network of health professionals, hospitals, and health services,  as  well  as  the  sales  and  client  support  needed  for  Osteopore  to drive uptake amongst surgeons within the sector.

Osteopore will work closely with MAXONIQ to train and support sales representatives to facilitate ongoing promotion across Australia and New Zealand.

MAXONIQ has an extensive sales team and  clinical  support  coverage  with  developed  and  recognised  expertise  for  the promotion of Osteopore’s products.

 

Increasing reputation beyond cranial implants

The distribution deal is part of a series of initiatives by Osteopore to increase accessibility to its products to surgeons globally.

Several key distributor partnerships undertaken by Osteopore recently include in Spain and Colombia, some of which are already generating revenue.

Osteopore has built a solid reputation for its cranial implants. In early March, Osteopore commenced a study in partnership with Singular Health (ASX: SHG), aimed at improving the accuracy and workflow efficiency of Osteopore’s customised cranial implants.

Such highly-customised implants are developed through CT scans of patients, which are then processed by software that converts them into 3D models, from which the 3D print implants are created.

Osteopore Executive Chairman Mark Leong said the MAXONIQ  partnership will further its reputation beyond the cranial implant sphere.

“This MAXONIQ partnership will help strengthen our company’s reach beyond the cranial space into the oral and maxillofacial (OMF) area, where our solutions have been successfully adopted in Asia,” he said.

“This also helps us gain a deeper foothold into our home market of Australia.”

MAXONIQ Managing Director,  Stuart Douglas said the company was excited by the  distribution opportunity with Osteopore in Australia and New Zealand to provide it with greater access to the oral and maxillofacial (OMF) surgical market.

“Founded by an Oral and Maxillofacial Surgeon to address unmet medical device needs, MAXONIQ now boasts a growing suite of oral and facial implants and  surgical  support  products  with  over  6  years  of  design  and  fabrication  experience,” Douglas said.

He said importantly, the addition of Osteopore technology will deliver access to a wider network of OMF surgeons.

“The partnership with Osteopore will allow focused specialist representation of Osteomesh for orbital floor repair and facilitate sales of patient specific implants for orbit reconstruction,” he said.

This article was developed in collaboration with Osteopore, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Read MoreBiotech

Featured Companies

You might be interested in